BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Levin MJ, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Weinberg A. Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Invest 2018;128:4429-40. [PMID: 30024861 DOI: 10.1172/JCI121484] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Park SY, Levin MJ, Canniff J, Johnson M, Schmid DS, Weinberg A. Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines. NPJ Vaccines 2022;7:123. [PMID: 36284110 DOI: 10.1038/s41541-022-00545-2] [Reference Citation Analysis]
2 Xia Y, Zhang X, Zhang L, Fu C. Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis. Front Immunol 2022;13:978203. [DOI: 10.3389/fimmu.2022.978203] [Reference Citation Analysis]
3 Nam HJ, Hong SJ, Lee A, Kim J, Lee S, Casper C, Carter D, Reed SG, Simeon G, Shin EC. An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21. NPJ Vaccines 2022;7:45. [PMID: 35459225 DOI: 10.1038/s41541-022-00467-z] [Reference Citation Analysis]
4 Bell MR, Kutzler MA. An old problem with new solutions: Strategies to improve vaccine efficacy in the elderly. Adv Drug Deliv Rev 2022;183:114175. [PMID: 35202770 DOI: 10.1016/j.addr.2022.114175] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, Hampel PJ, Holets MA, Darby HC, Slager SL, Kay NE, Miao C, Canniff J, Whitaker JA, Levin MJ, Schmid DS, Kennedy RB, Weinberg A, Parikh SA. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. Am J Hematol 2022;97:90-8. [PMID: 34699616 DOI: 10.1002/ajh.26388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Jahn S, Diamanti E, Heller T, Papageorgiou A, Herbst M. Zosterimpfung unter Biologikatherapie. ästhet dermatol kosmetol 2021;13:25-7. [DOI: 10.1007/s12634-021-1579-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Johnson MJ, Liu C, Ghosh D, Lang N, Levin MJ, Weinberg A. Cell-Mediated Immune Responses After Administration Of The Live Or The Recombinant Zoster Vaccine: Five-Year Persistence. J Infect Dis 2021:jiab580. [PMID: 34850039 DOI: 10.1093/infdis/jiab580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Pogostin BH, McHugh KJ. Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness. Bioengineering (Basel) 2021;8:155. [PMID: 34821721 DOI: 10.3390/bioengineering8110155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Weinberger B. Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. Immun Ageing 2021;18:38. [PMID: 34627326 DOI: 10.1186/s12979-021-00249-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Stephens LM, Varga SM. Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population. Vaccines (Basel) 2021;9:624. [PMID: 34207770 DOI: 10.3390/vaccines9060624] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
11 Schmid DS, Miao C, Leung J, Johnson M, Weinberg A, Levin MJ. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines. J Virol 2021;95:e00240-21. [PMID: 33762414 DOI: 10.1128/JVI.00240-21] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
12 Cao H, Wang Y, Luan N, Liu C. Immunogenicity of Varicella-Zoster Virus Glycoprotein E Formulated with Lipid Nanoparticles and Nucleic Immunostimulators in Mice. Vaccines (Basel) 2021;9:310. [PMID: 33805880 DOI: 10.3390/vaccines9040310] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
13 Gustafson CE, Kim C, Weyand CM, Goronzy JJ. Influence of immune aging on vaccine responses. J Allergy Clin Immunol 2020;145:1309-21. [PMID: 32386655 DOI: 10.1016/j.jaci.2020.03.017] [Cited by in Crossref: 115] [Cited by in F6Publishing: 122] [Article Influence: 115.0] [Reference Citation Analysis]
14 Caruso C, Aiello A, Pawelec G, Ligotti ME. Vaccination in old age: Challenges and promises. Human Aging 2021. [DOI: 10.1016/b978-0-12-822569-1.00020-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sandgren KJ, Truong NR, Smith JB, Bertram K, Cunningham AL. Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology. Methods Mol Biol 2020;2060:31-56. [PMID: 31617171 DOI: 10.1007/978-1-4939-9814-2_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
16 Karunakaran KP, Yu H, Jiang X, Chan QWT, Foster LJ, Johnson RM, Brunham RC. Discordance in the Epithelial Cell-Dendritic Cell Major Histocompatibility Complex Class II Immunoproteome: Implications for Chlamydia Vaccine Development. J Infect Dis 2020;221:841-50. [PMID: 31599954 DOI: 10.1093/infdis/jiz522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
17 Voic H, de Vries RD, Sidney J, Rubiro P, Moore E, Phillips E, Mallal S, Schwan B, Weiskopf D, Sette A, Grifoni A. Identification and Characterization of CD4+ T Cell Epitopes after Shingrix Vaccination. J Virol 2020;94:e01641-20. [PMID: 32999027 DOI: 10.1128/JVI.01641-20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
18 Wang Y, Qi J, Cao H, Liu C. Immune Responses to Varicella-Zoster Virus Glycoprotein E Formulated with Poly(Lactic-co-Glycolic Acid) Nanoparticles and Nucleic Acid Adjuvants in Mice. Virol Sin 2021;36:122-32. [PMID: 32757147 DOI: 10.1007/s12250-020-00261-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
19 Voic H, de Vries RD, Sidney J, Rubiro P, Moore E, Phillips E, Mallal S, Schwan B, Weiskopf D, Sette A, Grifoni A. Identification and characterization of CD4+ T cell epitopes after Shingrix vaccination.. [DOI: 10.1101/2020.07.29.227082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wang ZB, Xu J. Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant-Antigen Codelivery. Vaccines (Basel) 2020;8:E128. [PMID: 32183209 DOI: 10.3390/vaccines8010128] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 26.0] [Reference Citation Analysis]
21 Dagnew AF, Klein NP, Hervé C, Kalema G, Di Paolo E, Peterson J, Salaun B, Schuind A. The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine. J Infect Dis 2021;224:1139-46. [PMID: 32103273 DOI: 10.1093/infdis/jiaa083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
22 Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing 2019;16:25. [PMID: 31528180 DOI: 10.1186/s12979-019-0164-9] [Cited by in Crossref: 200] [Cited by in F6Publishing: 206] [Article Influence: 66.7] [Reference Citation Analysis]
23 Weinberg A, Pang L, Johnson MJ, Caldas Y, Cho A, Tovar-Salazar A, Canniff J, Schmader KE, Popmihajlov Z, Levin MJ. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity. J Virol 2019;93:e00305-19. [PMID: 31092579 DOI: 10.1128/JVI.00305-19] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
24 Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence: A systems-level overview of immune cell biology and strategies for improving vaccine responses. Exp Gerontol 2019;124:110632. [PMID: 31201918 DOI: 10.1016/j.exger.2019.110632] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 16.7] [Reference Citation Analysis]
25 Truong NR, Smith JB, Sandgren KJ, Cunningham AL. Mechanisms of Immune Control of Mucosal HSV Infection: A Guide to Rational Vaccine Design. Front Immunol 2019;10:373. [PMID: 30894859 DOI: 10.3389/fimmu.2019.00373] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
26 Nordén R, Nilsson J, Samuelsson E, Risinger C, Sihlbom C, Blixt O, Larson G, Olofsson S, Bergström T. Recombinant Glycoprotein E of Varicella Zoster Virus Contains Glycan-Peptide Motifs That Modulate B Cell Epitopes into Discrete Immunological Signatures. Int J Mol Sci 2019;20:E954. [PMID: 30813247 DOI: 10.3390/ijms20040954] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
27 Levin MJ, Weinberg A. Immune responses to zoster vaccines. Hum Vaccin Immunother 2019;15:772-7. [PMID: 30676834 DOI: 10.1080/21645515.2018.1560918] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
28 Perciani CT, Farah B, Kaul R, Ostrowski MA, Mahmud SM, Anzala O, Jaoko W, MacDonald KS; KAVI-ICR Team. Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation. J Clin Invest 2019;129:875-86. [PMID: 30511963 DOI: 10.1172/JCI124473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
29 Sorel O, Messaoudi I. Varicella Virus-Host Interactions During Latency and Reactivation: Lessons From Simian Varicella Virus. Front Microbiol 2018;9:3170. [PMID: 30619226 DOI: 10.3389/fmicb.2018.03170] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
30 Syed YY. Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster. Drugs Aging 2018;35:1031-40. [DOI: 10.1007/s40266-018-0603-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
31 Gershon AA. Tale of two vaccines: differences in response to herpes zoster vaccines. J Clin Invest 2018;128:4245-7. [PMID: 30179221 DOI: 10.1172/JCI123217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]